BAX Baxter International, Inc.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Company profile
Ticker
BAX
Exchange
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
3M • Stryker • ResMed • Integra Lifesciences • Hill-Rom • Haemonetics • NuVasive • AngioDynamics • Merit Medical Systems • Globus Medical ...
SEC CIK
Corporate docs
IRS number
360781620
BAX stock data
()
Calendar
30 Jul 19
22 Sep 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 2.84B | 2.63B | 2.84B | 2.77B | |
| Net income | 343M | 347M | 348M | 544M | |
| Diluted EPS | 0.66 | 0.66 | 0.65 | 1 | |
| Net profit margin | 12.08% | 13.18% | 12.25% | 19.66% | |
| Operating income | 355M | 384M | 398M | 385M | |
| Net change in cash | 1.02B | 76M | -1.03B | 3M | |
| Cash on hand | 2.93B | 1.91B | 1.83B | 2.86B | |
| Cost of revenue | 1.68B | 1.55B | 1.65B | 1.53B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 11.13B | 10.56B | 10.16B | 9.97B | |
| Net income | 1.62B | 717M | 4.97B | 968M | |
| Diluted EPS | 2.97 | 1.29 | 9.01 | 1.76 | |
| Net profit margin | 14.60% | 6.79% | 48.85% | 9.71% | |
| Operating income | 1.6B | 1.29B | 745M | 573M | |
| Net change in cash | -1.56B | 593M | 588M | -712M | |
| Cash on hand | 1.83B | 3.39B | 2.8B | 2.21B | |
| Cost of revenue | 6.35B | 6.09B | 6.05B | 5.78B |
Financial data from company earnings reports
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AAKHI, absence, bundled, comparison, dedesignated, dialyzer, disease, EVO, fourth, health, Indenture, IQ, Mellon, necessitating, PrisMax, proposed, prosecution, repaid, stage, strong, Trust, Trustee, Twelfth
Removed:
adjusted, arising, core, improved, initiated, moving, nonstrategic, presenting, salary, unrecognized
Financial reports
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
5 Nov 18
10-Q
2018 Q2
Quarterly report
6 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
7 Aug 17
10-Q
2017 Q1
Quarterly report
4 May 17
Current reports
8-K
Baxter Reports Second-quarter 2019 Results
25 Jul 19
8-K
Other Events
15 May 19
8-K
Submission of Matters to a Vote of Security Holders
10 May 19
8-K
Baxter Reports First-quarter 2019 Results
25 Apr 19
8-K
Departure of Directors or Certain Officers
21 Mar 19
8-K
Departure of Directors or Certain Officers
28 Feb 19
8-K
Baxter Reports 2018 Fourth-quarter and Full-year Results
31 Jan 19
8-K
Baxter Appoints Patricia Morrison and Amy Wendell to Its Board
6 Dec 18
8-K
Departure of Directors or Certain Officers
15 Nov 18
8-K
Baxter Reports Third-quarter 2018 Results and Updates Financial Outlook
31 Oct 18
Registration and prospectus
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19
S-3ASR
Automatic shelf registration
23 Aug 18
8-A12B
Registration of securities on exchange
30 May 17
424B2
Prospectus for primary offering
22 May 17
424B5
Prospectus supplement for primary offering
19 May 17
FWP
Free writing prospectus
19 May 17
424B5
Prospectus supplement for primary offering
12 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
23 Mar 18
DEFA14A
Additional proxy soliciting materials
23 Mar 18
DEF 14A
Definitive proxy
17 Mar 17
DEFA14A
Additional proxy soliciting materials
17 Mar 17
DEF 14A
Definitive proxy
24 Mar 16
DEFA14A
Additional proxy soliciting materials
24 Mar 16
PRE 14A
Preliminary proxy
14 Mar 16
DEF 14A
Definitive proxy
25 Mar 15
Other
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
30 May 17
UPLOAD
Letter from SEC
10 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
14 Apr 17
UPLOAD
Letter from SEC
31 Mar 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16